Inspecs Group's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 51.22.
Inspecs Group's Days Inventory for the
six
months ended in Dec. 2025 was 177.3.
Inspecs Group's Days Payable for the
six
months ended in Dec. 2025 was 89.91.
Therefore, Inspecs Group's Cash Conversion Cycle (CCC) for the
six
months ended in Dec. 2025 was 138.61.
Inspecs Group (OTCPK:INPEF) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Inspecs Group Cash Conversion Cycle Related Terms
Inspecs Group Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Inspecs Group's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INPEF vs ISRG, BDX, MDLN: Cash Conversion Cycle Comparison
For the Medical Instruments & Supplies subindustry, Inspecs Group's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inspecs Group Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Inspecs Group's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Inspecs Group's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Inspecs Group's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inspecs Group (INPEF) has a Cash Conversion Cycle of 138.61 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Inspecs Group and its competitors.
Is Inspecs Group's Cash Conversion Cycle too high?
Inspecs Group's current Cash Conversion Cycle is 138.61. The Medical Devices & Instruments industry median Cash Conversion Cycle is 156.96. Inspecs Group's value of 138.61 is 11.7% below this industry median. Overall, Inspecs Group has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Inspecs Group's Cash Conversion Cycle compare to ISRG and BDX?
Inspecs Group's Cash Conversion Cycle of 138.61 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 156.96. Inspecs Group's value of 138.61 is 11.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 156.96, based on 818 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inspecs Group's current Cash Conversion Cycle of 138.61 is 11.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Inspecs Group and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 156.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inspecs Group's current Cash Conversion Cycle is 138.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inspecs Group stock overvalued right now?
Inspecs Group (INPEF) has a current Cash Conversion Cycle of 138.61. The stock's GF Value™ is $0.65, compared to a current price of $1.08 — trading 66.2% above its estimated fair value. The current Cash Conversion Cycle is 138.61 and 11.7% below the Medical Devices & Instruments industry median of 156.96. Inspecs Group's overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Inspecs Group (INPEF), the current Cash Conversion Cycle is 138.61 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inspecs Group (INPEF) Overvalued in 2026?
Based on GuruFocus' analysis, Inspecs Group stock appears to be overvalued.
The current stock price of $1.08 is trading 66.2% above its estimated GF Value™ of $0.65.
Key valuation signals for INPEF:
Cash Conversion Cycle: 138.61
GF Value™: $0.65 vs. price of $1.08 (66.2% above fair value)
Industry Position: 11.7% below the Medical Devices & Instruments median
No single metric tells the full story. See the INPEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inspecs Group PLC is a designer and manufacturer of eyewear frames and accessories. The customers of the company include optical and Non-optical retailers, distributors, and independent opticians. The company operations are spread across the United Kingdom, Europe (excluding the UK), South America, North America, Asia, Africa, and Australia. Its eyewear brands include Superdry, Titanflex, O'Neill, Brendel, Humphreys, Marc O'Polo, and among others. The reporting segments of the company are Frames and Optics product distribution which derives maximum revenue, and Manufacturing includes OEM and manufacturing distribution segment.
52GF Score
Get the complete analysis for INPEF
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INPEF has been successfully added to your 
